Prevention, diagnosis and treatment of cervical cancer: A systematic review of the impact of COVID-19 on patient care

Ferrara, Pietro; Dallagiacoma, Giulia; Alberti, Federica; Gentile, Leandro; Bertuccio, Paola; Odone, Anna

doi:10.1016/j.ypmed.2022.107264

Cited by 18 publications

(16 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For the tumor site cervix uteri, we observed, in contrast to other studies (Ferrara et al 2022 ), a large increase in newly diagnosed cases during the COVID-19 pandemic as compared to the pre-pandemic period, especially for carcinoma in situ with a significant doubling of cases. Several factors may explain this finding.…”

Section: Discussioncontrasting

confidence: 99%

Impact of the COVID-19 pandemic on reported cancer diagnoses in Bavaria, Germany

Voigtländer¹,

Hakimhashemi²,

Grundmann³

et al. 2023

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose The aim of our study was to explore the impact of the COVID-19 pandemic on reported cancer cases in Bavaria, Germany, by comparing pre-pandemic (March 2019 to February 2020) and pandemic period (March 2020 to February 2021). Methods Data on incident cases were retrieved from the Bavarian Cancer Registry (until 22nd April 2022). We included patients with malignant and in situ neoplasms reported by pathology departments with consistent reporting. We calculated the number of incident cases during the COVID-19 pandemic and the pre-pandemic period with 95% confidence intervals (CI) with Bonferroni correction (α = 0.0018) based on a Poisson approach. We stratified for malignancy (malignant, in situ), tumor site, and month of year. Results Data was available for 30 out of 58 pathology departments (51.7%) from Bavaria. Incident malignant neoplasms dropped from 42,857 cases in the pre-pandemic period to 39,980 cases in the pandemic period (− 6.7%; 95% CI − 8.7%, − 4.7%). Reductions were higher for colon, rectum, skin/melanoma as well as liver (> 10.0% reduction) and less for breast cancer (4.9% reduction). No case reductions were observed for pancreas, esophagus, ovary, and cervix. Percent changes were largest for April 2020 (− 20.9%; 95% CI − 24.7%, − 16.8%) and January 2021 (− 25.2%; 95% CI − 28.8%, − 21.5%) compared to the previous year. Declines tended to be larger for in situ compared to malignant neoplasms. Conclusion Detection and diagnosis of cancer were substantially reduced during the COVID-19 pandemic. Potential effects, e.g. a stage shift of tumors or an increase of cancer mortality, need to be monitored.

show abstract

Section: Discussioncontrasting

confidence: 99%

Impact of the COVID-19 pandemic on reported cancer diagnoses in Bavaria, Germany

Voigtländer¹,

Hakimhashemi²,

Grundmann³

et al. 2023

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…For context, the omicron variant surge started in December 2021 with a surge of both omicron and delta variants occurring in January 2022. 23 , 24 We suspect that the increase in missed opportunities during this time period was due to pandemic-associated issues including vaccine refusal secondary to an increased number of sick visits and high staff turnover with many new staff forgetting to recommend HPV vaccination. It is possible that parents refused vaccination because of concern for the HPV vaccination at a young age but more likely other factors were involved.…”

Section: Discussionmentioning

confidence: 99%

Does HPV vaccination initiation at age 9, improve HPV initiation and vaccine series completion rates by age 13?

O’Leary

Frost

2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Vaccination for Human Papillomavirus (HPV) is important to reduce rates of cervical and oropharyngeal cancer. We aimed to evaluate if a program to initiate HPV vaccination at 9 years improved initiation and completion rates by 13 years of age. Data on empaneled patients aged 9–13 years from January 1, 2021 to August 30, 2022 were abstracted from the electronic health record. Primary outcome measures included HPV vaccination initiation and series completion by 13 years of age. The secondary outcome measure was missed opportunities for HPV vaccination. In total, 25,888 patients were included (12,433 pre-intervention, and 13,455 post-intervention). The percentage of patients aged 9–13 with an in-person visit who received at least 1 dose of HPV vaccine increased from 30% pre-intervention to 43% post-intervention. The percentage of patients who received 2 doses of vaccine increased from 19.3% pre-intervention to 42.7% post-intervention. For the overall population seen in-person, initiation of HPV vaccination by age 13 years increased from 42% to 54%. HPV completion increased as well (13% to 18%). HPV vaccination initiation at 9 years of age may be an acceptable and effective approach to improving vaccination rates.

show abstract

“…We found neither a significant difference between the total score points of both cohorts nor a worsening of prognostic outcome and therapy failure in the COVID-19 cohort. This is in particular remarkable as other clinical disciplines experienced significant impairments in the diagnosis and treatment of diseases during the first waves of the COVID-19 pandemic [22][23][24]. On the one hand, these different observations might be due to biased awareness of healthcare professionals in favor of infectious diseases.…”

Section: Discussionmentioning

confidence: 99%

Impact of the COVID-19 Pandemic on the Management of Staphylococcus aureus Bloodstream Infections in a Tertiary Care Hospital

Böing

Froböse²,

Schaumburg³

et al. 2023

Pathogens

View full text Add to dashboard Cite

Staphylococcus aureus bacteremia (SAB) is associated with a high mortality rate. The clinical outcome of SAB patients highly depends on early diagnosis, adequate antibiotic therapy and source control. In the context of the COVID-19 pandemic, the health care system faced additional organizational challenges and the question arose whether structured screening and triaging for COVID-19 and shifting resources influence the management of SAB. Patients (n = 115) with SAB were enrolled in a retrospective comparative study with historical controls (March 2019–February 2021). The quality of SAB therapy was assessed with a point score, which included correct choice of antibiotic, adequate dosage of antibiotic, sufficient duration of therapy, early start of therapy after receipt of findings, focus search and taking control blood cultures 3–4 days after starting adequate antibiotic therapy. The quality of treatment before and after the onset of the COVID-19 pandemic were compared. No significant differences in the total score points were found between the pre-COVID-19 and COVID-19 cohort. All quality indicators, except the correct duration of antibiotic therapy, showed no significant differences in both cohorts. Furthermore, there were no significant differences in the outcome between both cohorts. The treatment quality of SAB therapy was comparable before and during the COVID-19 pandemic.

show abstract

Prevention, diagnosis and treatment of cervical cancer: A systematic review of the impact of COVID-19 on patient care

Cited by 18 publications

References 63 publications

Impact of the COVID-19 pandemic on reported cancer diagnoses in Bavaria, Germany

Impact of the COVID-19 pandemic on reported cancer diagnoses in Bavaria, Germany

Does HPV vaccination initiation at age 9, improve HPV initiation and vaccine series completion rates by age 13?

Impact of the COVID-19 Pandemic on the Management of Staphylococcus aureus Bloodstream Infections in a Tertiary Care Hospital

Contact Info

Product

Resources

About